Back to Search
Start Over
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
- Source :
- The Lancet Gastroenterology & Hepatology; September 2023, Vol. 8 Issue: 9 p790-802, 13p
- Publication Year :
- 2023
-
Abstract
- JNJ-73763989 (JNJ-3989), a small interfering RNA, targets all hepatitis B virus (HBV) RNAs, reducing all HBV proteins. JNJ-56136379 (JNJ-6379; also known as bersacapavir), a capsid assembly modulator, inhibits HBV replication. We aimed to evaluate the efficacy (ie, antiviral activity) and safety of these therapeutics in combination with nucleos(t)ide analogues in patients with chronic hepatitis B.
Details
- Language :
- English
- ISSN :
- 24681253
- Volume :
- 8
- Issue :
- 9
- Database :
- Supplemental Index
- Journal :
- The Lancet Gastroenterology & Hepatology
- Publication Type :
- Periodical
- Accession number :
- ejs63731076
- Full Text :
- https://doi.org/10.1016/S2468-1253(23)00148-6